Cargando…
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
The clinical application of immune checkpoint inhibitors (ICIs) has led to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC). Despite the observation of improved overall survival in NSCLC patients treated with ICIs, their efficacy varies greatly...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115923/ https://www.ncbi.nlm.nih.gov/pubmed/30060457 http://dx.doi.org/10.3390/cancers10080245 |